Last reviewed · How we verify
NCT06203730: MHD
Study on the Influence of Dyadic Psychoeducational Intervention on Patients With Maintenance Hemodialysis
NA trial testing dyadic psychological intervention strategy in End Stage Renal Disease on Dialysis in 80 participants. Currently enrolling.
1 July 2024
Quick facts
| Lead sponsor | Jiangsu Taizhou People's Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 January 2024 |
| Primary completion | 1 July 2024 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- dyadic psychological intervention strategy
Conditions studied
- End Stage Renal Disease on Dialysis — all drugs for End Stage Renal Disease on Dialysis →
Sponsor
Jiangsu Taizhou People's Hospital
Who can join
18 and older, any sex, with End Stage Renal Disease on Dialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims explored the effectiveness of dual psychological intervention strategies in improving the quality of life of MHD patients based on the theoretical guidance of double ABC-X model. To provide a scientific and effective dual psychological intervention strategy for MHD patients and their caregivers, in order to improve the quality of life of MHD patients, and to provide a reference for nurses in clinical blood purification centers to implement psychological intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of dyadic psychoeducational interventions for haemodialysis patients and their family caregivers: a randomised controlled trial.
Zhang L, Chen Y, Tang W, Wang Q, et al · · 2025 · cited 1× · PMID 40038667 · DOI 10.1186/s12912-025-02835-1
Verify or expand the search:
- PubMed search for NCT06203730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Renal Disease on Dialysis
Currently open trials in the same condition.
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT07016841 — Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins · recruiting
- NCT05654103 — Comparing Surgical and Endovascular Arteriovenous Fistula Creation · NA · recruiting
- NCT06483074 — Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients · Phase 2 · recruiting
- NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting
Other Jiangsu Taizhou People's Hospital trials
Trials by the same sponsor.
- NCT07532239 — Survey of Knowledge, Practice, and Recommendation Behaviors Regarding Healthy Lifestyles Among Healthcare Workers · not yet recruiting
- NCT07492498 — Telemedicine-Based Integrated Care for Heart Failure Prevention in Older Patients With Atrial Fibrillation (MIRACLE-AF I · NA · not yet recruiting
- NCT07492524 — Telemedicine-based Integrated Management of Atrial Fibrillation and Heart Failure in Older Patients in Village Clinics · NA · not yet recruiting
- NCT07332962 — fMRI Evaluation of Auricular Acupuncture Targets: An Exploratory Clinical Study · NA · recruiting
- NCT06545799 — Construction of a Cohort for Pan-Vascular Disease Among Employees of Taizhou People's Hospital · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06203730 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Taizhou People's Hospital
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06203730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing